Related Experiment Videos
CA 19-9 and CA 125 determination by immunoluminometric assay
M Plebani1, D Faggian, M Masiero
1Cattedra e Servizio di Biochimica Clinica, Università di Padova, Italia.
Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie
|December 1, 1990
Summary
A new immunoluminometric assay (ILMA) accurately measures cancer antigens CA 19-9 and CA 125 in serum. This reproducible technique shows excellent linearity and recovery, correlating well with existing methods.
Area of Science:
- Clinical Chemistry
- Immunoassays
- Oncology Diagnostics
Background:
- Cancer antigen testing is crucial for diagnosis and monitoring.
- Existing methods for CA 19-9 and CA 125 measurement have limitations.
- Development of novel, reliable diagnostic assays is essential.
Purpose of the Study:
- To evaluate a new immunoluminometric assay (ILMA) for serum CA 19-9 and CA 125.
- To assess the reproducibility, linearity, and analytical recovery of the ILMA.
- To compare ILMA results with established immunoradiometric assays (IRMA).
Main Methods:
- Serum samples were analyzed using the novel ILMA.
- Reproducibility was assessed via within-run and between-run coefficients of variation.
- Linearity and analytical recovery were determined.
- ILMA results were correlated with IRMA results using regression analysis.
Main Results:
- The ILMA demonstrated satisfactory reproducibility (CVs 4.2–7.3%).
- Assay linearity was maintained across a wide concentration range.
- Mean analytical recovery was high: 94% for CA 19-9 and 98% for CA 125.
- Significant agreement was found between ILMA and IRMA for both CA 125 (r=0.966) and CA 19-9 (r=0.995).
Conclusions:
- The evaluated immunoluminometric assay is a reproducible and accurate method for measuring serum CA 19-9 and CA 125.
- ILMA shows excellent correlation with established immunoradiometric assays.
- This novel assay offers a reliable alternative for cancer antigen diagnostics.